Clinical Trials

Noxopharm begins NOXCOVID-1 trial of Veyonda in Europe

Noxopharm has launched a clinical programme, called NOXCOVID, for its Covid-19 drug candidate Veyonda by starting a phase 1 trial in Europe.

Low Maintenance pH Electrodes and Systems

METTLER TOLEDO follows in the tradition of INGOLD by continuing to provide innovative new products and systems based on decades of accumulated knowledge and experience in industrial measurement technology.

PT010 significantly reduced rate of moderate or severe COPD exacerbations in ETHOS trial

Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Novaremed gets FDA nod for phase 2 trial of NRD135S.E1 for PDPN

Novaremed, a clinical-stage Swiss biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate its US-based Phase 2 clinical study of the novel drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN).

Merck’s V114 pneumococcal vaccine candidate succeeds in two phase 3 trials

Merck said that V114, its investigational 15-valent pneumococcal conjugate vaccine candidate, has met safety and immunogenicity goals in two initial phase 3 trials in adults.

Elemental Packaging

After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.

Roche’s Tecentriq plus chemotherapy meets goal in triple-negative breast cancer trial

Roche announced that Tecentriq (atezolizumab) plus chemotherapy has achieved primary endpoint in the trial of patients with triple-negative breast cancer (TNBC).

Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial

Merck, known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries.

SC formulation of DARZALEX combination delivers deep and rapid haematologic responses and improved clinical outcomes in newly diagnosed light chain amyloidosis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomised Phase 3 study investigating the subcutaneous (SC) formulation of DARZALEX (daratumumab) in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.